7 min
0
Scientists confirmed for the first time that cancer cell PD-L1 does not inhibit T cell toxicity, but inhibits T cell infiltration into metastatic lesions
After PD-1/PD-L1 inhibitors have been used in cancer immunotherapy for nearly 10 years, scientists are still discovering new mechanisms to replenish our knowledge around PD-L1.